PubMed Health⌕ Search

Biomedical subjects

G Murialdo

Publications and source records attributed to G Murialdo.

At least 55 records · Page 3Linked to original sources
PubMed1982

Neuroendocrinological and clinical data upon trazodone treatment in depressed patients.

Prolactin and somatotropin secretory rhythmicity was studied in 7 inhibited depression male patients, evaluated by the Hamilton Rating Scale for depression, before and after trazodone (400 mg i.v. once daily) treatment. The mean 24-hour hormone levels of the patients were comparable to the controls. Trazodone enhances the prolactin value, increasing chiefly the titres during sleep which were lower in respect to controls before treatment. The drug decreases the mean 24-hour somatotropin levels, mainly the values during sleep. A serotoninergic effect is possibly involved. An improvement of mood has been observed in all cases.

Adult↗
PubMed1981

Electroencephalographic effects of two short chain ACTH analogues.

The effects of two short chain ACTH analogues, tetracosactide 1-24, eptadecapeptide 1-17, on EEG, behaviour and temperature of the rabbit are studied. The behaviour and temperature effects of two compounds are quite similar. The EEG synchronizing action is more evident when tetracosactide 1-24 is administered. This fact suggests that the aminoacids 18-24 might be important in affecting electric cerebral activity.

Adrenocorticotropic Hormone↗
PubMed1980

Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea.

Plasma prolactin (PRL) and growth hormone (GH) levels were measured in 8 patients with Parkinson's disease (PD) and in 6 patients with Huntington's chorea (HC) during the night. The sleep was evaluated with all-night poligraphic recordings. Plasma PRL levels were significantly lower in parkinsonian patients than in age-matched controls. Plasma GH values did not differ between the two groups. In HC patients no statistically significant differences were found in the PRL and GH secretory patterns when compared to the age-matched control subjects. These data indicate that changes of nocturnal PRL and GH profile in PD and HC patients in respect to age-matched healthy subjects, may be present, but a straight forward differentiation among groups is not possible because of the wide individual variations.

Aged↗
PubMed1980

Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.

Single doses of carbidopa and benserazide, two inhibitors of aromatic aminoacids decarboxylase, have been given orally to healthy women and men aged 19 to 32 years. Serum prolactin levels increased in respect to baseline levels when 80, 125 or 250 mg of carbidopa and 10, 20, 30, 50, 80 or 125 mg of benserazide were given. The carbidopa doses of 20 and 50 mg were ineffective. Carbidopa induced the enhancement of serum prolactin at a later time and over a longer time span than benserazide. The effect on serum prolactin is dose dependent for both drugs. The hyperprolactinaemia obtained with 250 mg of carbidopa and with 125 mg of benserazide is significantly larger in women than in age matched men. The observed prolactin increase fits with the hypothesis that a diminution of the inhibitory effect of dopamine at the pituitary and/or at the median eminence levels may occur in connection to the pharmacologically impaired monoamine synthesis. An effect of serotonin cannot, however, be excluded.

Administration, Oral↗
PubMed1979

Effects of the inhibition of aromatic aminoacids decarboxylase on prolactin secretion in humans.

Carbidopa, at the dose of 250 mg. and benserazide at the dose of 125 mg, given orally in a single dose to healthy women aged between 23 - 26 years enhance significantly serum prolactin. The effect is not shared by two other inhibitors of AADC, namely alpha-methyl DOPA (500 mg) and fentiazac (400 mg). The effect of benserazide is suppressed by bromocriptine (2.5 mg) and blunted by 1-DOPA (400 mg) given orally simultaneusly.

Adult↗
PubMed1979

Dose and sex related effects of benserazide on prolactin secretion.

Benserazide, given orally at various doses ranging from 10 to 125 mg. to healthy women aged 21 to 33 years induces a dose related increase of prolactin titres in serum. When 125 mg are administered the percent increase of the hormone is larger in women than in men.

Adult↗
PubMed1979

Lack of counteracting effect of liposomes on benserazide-induced hyperprolactinemia.

Benserazide induces an increase of serum prolactin in man, possibly as the result of an impairment of the dopamine effect on the pituitary and/or on the outer median eminence caused by the inhibition on L-dopa decarboxylase. On the other hand, liposomes obtained from bovine brain cortex phospholipids reduced serum prolactin possibly through an effect of phosphatidylserine on dopamine biosynthesis at the level of tyrosine hydroxylase. Benserazide, given orally (125 mg) to 5 normal subjects, induced an increase of serum prolactin that did not change when 300 mg of phospholipid liposomes were given intravenously 60 min later. An increase of L-dopa synthesis does not seen to be capable to overcome the effects of the decarboxylase inhibition.

Adult↗
PubMed1979

Benserazide induces migraine attacks. Irrelevance of concomitant hyperprolactinemia.

Migrainous women underwent acute administration of sulpiride (25 mg i.v.) and benserazide (125 mg per os), both drugs increasing prolactin secretion. A similar increase in prolactin levels was found following the administration of the two drugs. A typical migraine attack was observed only in the 4 women given benserazide. These data, though being preliminary, stress the scarce or irrelevant role of prolactin in the pathogenesis of the migraine attack.

Adult↗